STAT Plus: A mysterious startup launched with an impossibly ambitious rallying cry. Now its plans are coming into focus
Before biotech darling Juno Therapeutics was “Juno Therapeutics,” the company had a pluckier name: FC…
Author: STAT
This company wants to make a once-a-month option for birth control pills
What if you could take your birth control pill just once a month? That’s the…
STAT Plus: Teva and Endo reach settlements with California over pay-to-delay deals
Three drug makers — including Teva Pharmaceutical (TEVA) and Endo International (ENDP) — agreed to…
Trump administration to reduce length of opioid prescriptions for federal employees
WASHINGTON — The government’s employee health plan will tighten its rules for covering prescription opioid…
Opinion: New guidelines on severe brain injury complicate already difficult decisions
When someone sustains a serious brain injury and is unresponsive, how soon can doctors say…
Opinion: Grassley: For Medicaid, greater transparency will open the door to better value and outcomes
Medicaid provides roughly 65 million Americans with health care coverage paid for by taxpayers. This…
STAT Plus: We have answers to some of biotech’s burning questions for 2019 — and some new issues to watch
So, how’s it going? Last January, we compiled a list of “burning questions” for a…
Déjà vu all over again: Another year passes without approval of new suppliers of marijuana for research
WASHINGTON — Forgive us if you read our stories on this topic from 2017 and…
STAT Plus: ‘Don’t be a Bernie Bro’: Inside conservatives’ brazen campaign to sabotage Trump’s signature drug pricing plan
WASHINGTON — The conservative health policy minds asked to gather at the White House on…
Despite calls to start over, U.S. health system covers 90% of Americans
WASHINGTON, D.C. — America’s much-maligned health care system is covering 9 out of 10 people,…
Study: 2% of women have ‘persistent’ opioid use after childbirth
Physicians thinking about prescribing opioid painkillers for women around the time of delivery should think…
STAT Plus: A Q&A with NIA’s director on Alzheimer’s: What’s gone wrong, and what’s going right?
Alzheimer’s disease has become one of the top health priorities in the U.S.: More than…
STAT Plus: A richly funded CRISPR alternative has a reproducibility problem
Back in 2016, a company called Homology Medicines came into the world with the claim…
Listen: Vertex’s regime change, the return of Ebola, & the rise of digital health
What makes an epidemic newsworthy? Can biotech succession succeed? And what’s so novel about digital…
STAT Plus: Grassley to pharma: Support my drug pricing bill, or get ready to roll the dice with Trump
WASHINGTON — The Senate’s most senior Republican, facing backlash from drug makers and his own…
STAT Plus: Consumer groups urge Italian and Belgian authorities to investigate Biogen over Spinraza pricing
A pair of consumer advocacy groups wants antitrust authorities in Italy and Belgium to investigate…
Opinion: The real public health emergency of international concern: the DRC
The decision to declare the yearlong Ebola outbreak in the Democratic Republic of the Congo…
First CRISPR study inside the body to start in U.S.
Patients are about to be enrolled in the first study to test a gene-editing technique…
STAT Plus: Key Senate committee advances its sweeping drug pricing bill — and keeps caps on price hikes
WASHINGTON — A key Senate committee on Thursday advanced a sweeping bill to lower drug…
STAT Plus: Here come the first true digital health IPOs. We’ve got 5 burning questions — and some answers
SAN FRANCISCO — Silicon Valley venture capital investors and Wall Street investment firms got in…
Elizabeth Warren presses Pfizer to fork over information on Scott Gottlieb
Sen. Elizabeth Warren is not done with Scott Gottlieb. Already peeved that the former Food…
STAT Plus: With a flood of amendments, some senators seek to water down drug-pricing bill
WASHINGTON — Lawmakers will wade through more than 100 potential amendments when the Senate Finance…
STAT Plus: Medicare paid for medicines that three other wealthy nations decided had little value
As the U.S. grapples with rising prices for medicines, a new analysis finds Medicare spent…
STAT Plus: 6 burning questions about the Senate Finance Committee’s ambitious new drug pricing plan
WASHINGTON — The Senate Finance Committee’s new bipartisan drug pricing package has the potential to…
STAT Plus: Sun Pharma sales rep claims he was fired for complaining about off-label marketing
A former Sun Pharmaceuticals sales rep has filed a lawsuit claiming he was fired for…
STAT Plus: Patients, backed by ‘dark money’ group, get ready to debate Duchenne drug prices. It will not be boring
Meetings of the Institute for Clinical and Economic Review don’t usually get one’s heart pumping….
Allergan recalls textured breast implant tied to rare cancer
WASHINGTON — Breast implant maker Allergan issued a worldwide recall Wednesday for certain textured models…
STAT Plus: California cites AmerisourceBergen for failing to flag huge sales of opioids to pharmacies
The state of California wants to revoke or suspend the wholesale license for a facility…
FDA cancels panel review of Intra-Cellular’s schizophrenia drug, causing shares to tumble
Shares of Intra-Cellular Therapies (ITCI) fell sharply Tuesday afternoon after the Food and Drug Administration…
STAT Plus: Massachusetts lawmakers approve compromise bill to lower Medicaid drug spending
Bowing to industry pressure, Massachusetts lawmakers on Monday approved a compromise measure that is designed…
STAT Plus: Frequency Therapeutics raises another $62 million
Less than a week after Frequency Therapeutics said it had cut a licensing deal with…
Merck unveils early data on HIV drug it says could be ‘a game changer’
At an all-day meeting for investors last month in a posh Manhattan event space, executives…
Senate committee unveils ambitious plan to cap drug price hikes, out-of-pocket expenses
WASHINGTON — A key Senate committee on Tuesday unveiled a long-awaited package of drug pricing…
STAT Plus: Pharmalittle: 23andMe’s Glaxo deal raises ethical questions; Dems to unveil drug pricing bill in September
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
Study: Millions should stop using aspirin for heart health
WASHINGTON — Millions of people who take aspirin to prevent a heart attack may need…
Acadia Pharma drug fails to improve psychosis in schizophrenia patients
A plan to expand the use of Acadia Pharmaceuticals’ only approved medicine to cover the…
Revamped OxyContin was supposed to reduce abuse, but has it?
WASHINGTON — Dr. Raeford Brown was uniquely positioned to help the U.S. government answer a…
.jpg)
STAT Plus: European Medicines Agency is advised to take steps to avoid bias concerns over approvals
Following a two-year inquiry, the European Ombudsman has recommended the European Medicines Agency take several…
A new kind of CAR-T becomes a micro-pharmacy, eliminating glioblastoma in mice
In immunotherapy for cancer, the buzziest area of research is combinations: one checkpoint drug with…
STAT Plus: Pharmalittle: Opioid companies failed to halt suspicious orders; U.K. diabetics are rationing insulin
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Opinion: Do as the doctor says, not as he or she does
Doctors are full of advice: Eat healthy. Exercise. Don’t miss your medications. Don’t get that…
STAT Plus: PhRMA scrambles to fight potential drug pricing reforms in budget deal
WASHINGTON — The drug industry’s lobbying group is calling on its lobbyists to push back…
STAT Plus: Biotech enters an era of ‘platform’ dominance
There was a time, back in biotech’s leaner years, when any company hoping to raise…
What the Ebola emergency means, what it doesn’t mean, and what’s next
Finally, the World Health Organization has declared the world’s latest Ebola outbreak a global health…
STAT Plus: Was it really a smart move for the FDA to approve a ‘smart pill’ for treating schizophrenia?
In late 2017, the Food and Drug Administration approved the first so-called smart pill, ushering…
Listen: Elon Musk’s monkey cyborg, Gilead’s shifting future, & an app for anxiety
Can apps treat anxiety? Is Gilead Sciences back on track? And are we all just…
.jpg)
STAT Plus: Pharmalittle: Women make ‘little progress’ in key pharma roles; FDA approves a Merck antibiotic
Rise and shine, everyone, another busy day is on the way. And this will be…
STAT Plus: Archived: An online chat discussing the past — and future — of Alzheimer’s research
After decades of attempts to develop treatments for Alzheimer’s disease, scientists still have precious little…
STAT Plus: Novartis sets aside $700 million to settle long-running bribery allegations in the U.S.
Novartis (NVS) has set aside $700 million to settle a long-running lawsuit in which the…
STAT Plus: Kronos, a startup led by Gilead alumni, raises $105 million in latest mega-round
Norbert Bischofberger, a former Gilead executive, has been running Kronos Bio for a little more…